PCVX
Vaxcyte, Inc.
NASDAQ · USHealthcareBiotechnology
$55.50-1.25%
Price as of Jul 20, 2026
PCVX financials
Vaxcyte, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $923.7M | $569.5M | $468.0M | $232.3M |
| Operating income | -$923.7M | -$569.5M | -$468.0M | -$232.3M |
| Net income | -$766.6M | -$463.9M | -$402.3M | -$223.5M |
| EBITDA | -$741.8M | -$448.1M | -$392.1M | -$214.0M |
| Basic EPS | $-5.63 | $-3.80 | $-4.14 | $-3.44 |
| Diluted EPS | $-5.63 | $-3.80 | $-4.14 | $-3.44 |
| Balance sheet | ||||
| Cash & equivalents | $174.0M | $387.9M | $397.5M | $834.7M |
| Total assets | $3.0B | $3.5B | $1.4B | $1.0B |
| Total liabilities | $360.5M | $205.5M | $167.4M | $52.6M |
| Stockholders’ equity | $2.7B | $3.3B | $1.2B | $953.6M |
| Total debt | $228.8M | $71.1M | $29.2M | $17.9M |
| Net debt | $54.9M | -$316.8M | -$368.2M | -$816.7M |
| Cash flow | ||||
| Operating cash flow | -$655.6M | -$452.6M | -$296.8M | -$170.6M |
| Capital expenditure | -$13.7M | -$22.4M | -$67.9M | -$5.8M |
| Free cash flow | -$669.3M | -$475.1M | -$364.7M | -$176.4M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |